Why the study?
Does aspirin prophylaxis reduce cardiovascular death or cancer mortality in people without prior CVD?
Population
people without prior CVD
Design
Review
Authors
Loading...
Does not support routine aspirin for primary prevention; leaves open net benefit in select high-risk subgroups.
Does aspirin prophylaxis reduce cardiovascular death or cancer mortality in people without prior CVD?
Routine use of aspirin for primary prevention is not warranted because the reduction in nonfatal MI is offset by bleeding risks without a mortality benefit.
Sreenivasa Rao Kondapally Seshasai (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: